The Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19 (ILIAD) Study found that the therapy significantly reduced viral load in 60 patients with mild to moderate illness and made them 4.10 times more likely to fall below the infectivity threshold by day seven of the onset of illness.

Lambda is a type III interferon (IFN) that stimulates immune responses that are critical for the development of host protection during viral infections. Binding to specific receptors leads to activation of the JAK-STAT signaling pathway and upregulation of numerous IFN-stimulated genes (ISGs).

"This is one of the first randomized controlled trials showing a significant effect on COVID-19 in an ambulatory setting," said study senior author Dr. Jordan Feld in a statement released by Eiger. "We are excited about these results showing that peginterferon lambda accelerates viral load decline in outpatients with mild to moderate COVID-19."

J&J pauses COVID-19 vaccine trials
Johnson & Johnson on October 12 temporarily paused further dosing in all of its COVID-19 vaccine clinical trials, including the phase III Ensemble...

Celltrion begins clinical trial for COVID-19 mAb
Celltrion has launched a phase III clinical trial investigating CT-P59, an anti-COVID-19 monoclonal antibody (mAb) treatment candidate.

Long-lasting IgG antibodies found in blood and saliva of COVID-19 patients
Researchers have discovered that immunoglobulin G (IgG) antibodies to the SARS-CoV-2 virus are longer lasting in the blood and saliva of COVID-19 patients...

Grifols begins trial for SARS-CoV-2 hyperimmune globulin
Grifols has started its anti-SARS-CoV-2 hyperimmune globulin clinical trial, named Inpatient Treatment with Anti-Coronavirus Immunoglobulin. The hyperimmune...

Will mutation of the SARS-CoV-2 virus affect vaccine effectiveness?
What impact will mutation of the SARS-CoV-2 virus have on the effectiveness of COVID-19 vaccines that are in development? In a new study published in...